Patients with Crohn’s disease (CD) frequently experience bowel urgency, a symptom resulting in rushing to the bathroom and sometimes causing loss of bowel control. The symptom of bowel urgency dramatically impacts patient quality of life (QoL), and can lead to depression, social isolation, disruption with work, interference with relationships and sexual intimacy, sleep disruptions, and fatigue. Bowel urgency is more commonly associated with ulcerative colitis, leading many gastroenterologists to forget to assess for this symptom in patients with CD or to only assess for it in patients with disease in the colon region. However, over 70% of patients with CD experience bowel urgency and it is reported as a common and disruptive symptom alongside pain and fatigue.
In this CME Outfitters webcast, expert faculty will discuss recognizing the frequency of bowel urgency in patients with CD and the impact to patient QoL, incorporating assessments for bowel urgency as part of thorough symptom evaluation for patients with CD, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes.
At the conclusion of this activity, learners will be able to better:
This activity is supported by an educational grant from Lilly.
Primary Audience: Gastroenterologists, physician associates (PAs), and nurse practitioners (NPs)
Secondary Audience: Nurses and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-021-H01-P).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 06/13/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Dubinsky reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Celltrion Inc.; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Spyre Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Other financial or material support: (PI) Janssen Biotech, Inc. Road to Prevention; (Co-PI) Helmsley Foundation PK Dashboard Optimized Dosing of Infliximab is not inferior to Standard Reactive Dosing: The OPTIMIZE Trial
Ms. Collins reports the following financial relationships:
Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Consultant: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: AbbVie Inc.; Lilly; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Long reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE
Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
The following individuals have no financial relationships to disclose:
Thai Nguyen, MD, MHA (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Cristina Carroll (Patient Planner)
Kasey Brandt, PharmD (Planning Committee)
John Jones, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
MMV-138-052024-11
